AP

Apollo Endosurgery IncNASDAQ APEN Stock Report

Last reporting period 31 Dec, 2022

Updated —

Last price

Market cap $B

0.58

Micro

Exchange

XNAS - Nasdaq

APEN Stock Analysis

AP

Uncovered

Apollo Endosurgery Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-35/100

Low score

Market cap $B

0.58

Dividend yield

Shares outstanding

47.549 B

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. The company is headquartered in West Lake Hills, Texas and currently employs 107 full-time employees. The company went IPO on 2005-04-21. The firm develops and distributes devices that are used by surgeons and gastroenterologists for various procedures related to gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. The firm's products include the OverStitch Endoscopic Suturing System, which enables advanced endoscopic procedures from within the Gastrointestinal tract, or endolumenally, by allowing physicians to suture, especially full-thickness, and secure the approximation of tissue. The X-Tack Endoscopic HeliX Tacking System is a suture-based device designed specifically for closing and healing defects in the lower gastrointestinal tract. The Orbera Intragastric Balloon System is a non-surgical alternative for interventional weight loss.

View Section: Eyestock Rating